Skip to main content

Table 1 General clinical features of enrolled patients

From: Liver resection of hepatocellular carcinoma in HIV-HCV co-infected patients: a retrospective case series

  HIV+/HCV+ HIV−/HCV+ p-value
Patients, n 5 11  
Sex, n (%)
 Male 5 (100) 8 (72.73) 0.509
 Female 0 3 (27.27)
Age (years)
 Mean ± SD (min; max) 53.2 ± 4.66 (49; 60) 62.54 ± 10.27 (48; 79) 0.076
 Median (25°; 75°) 51 (50; 56) 62 (64; 70.5)  
ECOG PS, n (%)
 0 5 (100) 8 (72.72) 0.509
 1 0 (0) 3 (27.27)
Comorbidities, n (%)
 Diabetes 1 (20) 1 (9.09) 0.99
 Heart failure 0 1 (9.09) 0.99
 Chronic kidney disease 0 0 1
 Respiratory insufficiency 0 3 (27.27) 0.509
 Previous abdominal surgery 2 (40) 7 (63.63) 0.596
Charlson comorbidity index
 Mean ± SD (min; max) 4.8 ± 1.09 (4; 6) 5.36 ± 1.36 (3; 8) 0.447
 Median (25°; 75°, %) 4 (4; 6) 5 (5; 6)  
 < 7 6 (100) 9 (81.81) 0.515
 ≥ 7 0 2 (18.18)
ASA score, n (%)
 1 0 1 (9.09) 0.99
 2 4 (80) 8 (72.72)
 3 1 (20) 2 (18.18)
Cirrhosis, n (%) 4 (80) 9 (81.81) 0.99
Child-Pugh class, n (%)
 A 4 (80) 11 (100)  
 B 1 (20) 0 0.315
 C 0 0  
MELD
 Mean ± SD (min; max) 9 ± 2.82 (6; 12) 9.18 ± 2.4 (7; 14) 0.895
 Median (25°; 75°, %) 8 (7; 12) 8 (8; 10)  
AFP ng/mL, n (%)
 ≤ 20 4 (100) 4 (40) 0.085
 > 20 0 6 (60)  
HCV treatment response, n (%)
 SVR 4 (80) 10 (90.9) 0.99
 Non-SVR 1 (20) 1 (9.09)  
Number of nodules at imaging, n 5 15  
 Mean (range) 1 (1; 1) 1.36 (1; 3) 0.244
Largest nodule diameter at imaging (mm)
 Mean ± SD 26.4 ± 14.2 29.3 ± 11 0.57
Portal vein thrombosis, n (%) 0 1 (9.09) 0.99
BCLC stage, n (%)
 0-A 5 (100) 9 (81.81) 0.99
 B-C 0 2 (18.18)  
Milan criteria, n (%)
 Out 0 (0) 2 (18.18) 0.99
 In 5 (100) 9 (81.81)  
  1. SD standard deviation; ECOG PS Eastern Cooperative Oncology Group Performance Status, ASA American Society of Anesthesiologist classification, MELD model for end-stage liver disease, AFP alpha-fetoprotein, SVR sustained virologic response, BCLC Barcelona Clinic Liver Cancer